Sugi Predict

Sugi Predict / Targets / PTPN22

PTPN22

Tyrosine-protein phosphatase non-receptor type 22 · Q9Y2R2 · PTPN22 on Sugi Atlas →

19,066 patent compounds predicted against PTPN22, 13,917 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL446371 SCHEMBL446371 0.48 8/20
SCHEMBL46215 SCHEMBL46215 0.67 5/20
SCHEMBL684266 SCHEMBL684266 0.59 5/20
Kumanon H Kumanon H (SCHEMBL150578) 1.00 4/20
SCHEMBL651434 SCHEMBL651434 0.54 4/20
SCHEMBL651435 SCHEMBL651435 0.54 4/20
SCHEMBL650337 SCHEMBL650337 0.44 4/20
SCHEMBL650338 SCHEMBL650338 0.44 4/20
SCHEMBL830605 SCHEMBL830605 0.43 4/20
SCHEMBL46552 SCHEMBL46552 0.75 3/20
SCHEMBL783008 SCHEMBL783008 0.53 3/20
SCHEMBL801547 SCHEMBL801547 0.53 3/20
SCHEMBL652210 SCHEMBL652210 0.37 3/20
1,2-Naphthoquinone 1,2-Naphthoquinone (SCHEMBL173316) 1.00 2/20
1,2-Naphthoquinone 1,2-Naphthoquinone (SCHEMBL203171) 0.74 2/20
SCHEMBL292030 SCHEMBL292030 0.70 2/20
1,2-Naphthoquinone 1,2-Naphthoquinone (SCHEMBL1363169) 0.69 2/20
1,2-Naphthoquinone 1,2-Naphthoquinone (SCHEMBL686745) 0.65 2/20
SCHEMBL1248923 SCHEMBL1248923 0.64 2/20
SCHEMBL1248925 SCHEMBL1248925 0.64 2/20

Clinical trials — most relevant to PTPN22 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy PHASE4COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Cyclosporine For The Treatment Of COVID-19(+) PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Immunoregulatory Therapy for 2019-nCoV PHASE2UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
rT3 and Inflammation in Hashimoto's Thyroiditis nanCOMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Resistance to Immunotherapy in Gastric Cancer nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome nanCOMPLETED
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus? nanCOMPLETED
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Use of miRNAs in Growth Hormone Deficiency (GHD) nanUNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN22 binder may also engage these)

ProteinNameSimilarity
A6QP06 — 0.993 A6QP06 →
P46200 — 0.992 P46200 →
Q2PFD7 — 0.990 Q2PFD7 →
Q9SB51 — 0.990 Q9SB51 →
Q8C0P0 — 0.990 Q8C0P0 →
PTPN12 Tyrosine-protein phosphatase non-receptor type 12 0.990 landscape →
Q6NTJ3 — 0.990 Q6NTJ3 →
Q90ZS6 — 0.990 Q90ZS6 →
P10244 — 0.989 P10244 →
Q949U2 — 0.989 Q949U2 →
P29352 — 0.989 P29352 →
P52550 — 0.989 P52550 →
Q3YC04 — 0.989 Q3YC04 →
NEDD4 E3 ubiquitin-protein ligase NEDD4 0.989 landscape →
B3NLX1 — 0.989 B3NLX1 →
Q92539 — 0.989 Q92539 →
Q9D2H8 — 0.989 Q9D2H8 →
Q99PI5 — 0.988 Q99PI5 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.988 landscape →
Q811D2 — 0.988 Q811D2 →
Q4JM28 — 0.988 Q4JM28 →
Q8C0P7 — 0.988 Q8C0P7 →
Q09354 — 0.988 Q09354 →
Q2YDH8 — 0.988 Q2YDH8 →
Q9XTN2 — 0.988 Q9XTN2 →
B2GUY1 — 0.988 B2GUY1 →
Q66HD5 — 0.988 Q66HD5 →
P70284 — 0.988 P70284 →
Q6ZV73 — 0.988 Q6ZV73 →
Q9NYI0 — 0.988 Q9NYI0 →